Tamoxifen
Also known as: Nolvadex, Nolva, Tamox
Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment
Overview
Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity.
Key benefits
- Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
- Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
- Restores endogenous testosterone production during post-cycle therapy
- Partial estrogen agonist activity in bone preserves bone mineral density
- Extremely long half-life allows for flexible dosing schedules
- Decades of clinical use with a well-characterized safety and efficacy profile
- Oral administration with no injections or reconstitution required
Mechanism of action
Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.
Molecular data
- Type
- Triphenylethylene-derived selective estrogen receptor modulator
- Half-life
- ~5-7 days
Indications
What the research community uses this compound for, with self-reported effectiveness.
Post-Cycle Therapy
Gynecomastia Prevention & Treatment
Medical (FDA-Approved)
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 40mg daily for 2 weeks, then 20mg daily for 2 weeks | Once daily for 4 weeks total | — |
| — | 20mg | Once daily for 4-6 weeks | — |
| — | 40mg daily for 2 weeks, then 20mg daily for 4 weeks | Once daily for 6 weeks total | — |
| — | 10-20mg | Once daily throughout cycle | — |
| — | 20mg | Once daily for 5-10 years | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Hot flashes and night sweats
- Nausea or gastrointestinal discomfort
- Mood swings, irritability, or emotional lability
- Fatigue during initial weeks of use
- Headache
Rare side effects
- Visual disturbances (blurred vision, corneal changes, retinal toxicity with long-term use)
- Deep vein thrombosis or pulmonary embolism (thromboembolic events)
- Endometrial changes including hyperplasia or endometrial cancer (primarily with long-term use exceeding 2 years)
- Elevated liver enzymes or hepatic steatosis
- Decreased libido or sexual dysfunction (paradoxical in some individuals)
Contraindications
- History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
- Known hypersensitivity to tamoxifen citrate or any excipients
- Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
- Pregnancy or planned pregnancy (category D -- known teratogenic risk)
- Pre-existing endometrial hyperplasia or uterine cancer
- Severe hepatic impairment
References
Primary literature and clinical-trial data informing this entry.